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Alcoholic liver disease (ALD) is a spectrum ranging from simple hepatic steatosis to alcoholic hepatitis and cirrhosis. Patients
with severe alcoholic hepatitis can have clinical presentation almost similar to those with decompensated cirrhosis. Scoring with
models like Maddrey discriminant function, a model for end-stage liver disease, Glasgow alcoholic hepatitis score, and Lille model
are helpful in prognosticating patients with ALD. One of the ﬁrst therapeutic goals in ALD is to induce alcohol withdrawal with
psychotherapy or drugs. Most studies have shown that nutritional therapy improves liver function and histology in patients with
ALD. The rationale for using glucocorticoids is to block cytotoxic and inﬂammatory pathways in patients with severe alcoholic
hepatitis. Pentoxifylline, a tumor necrosis factor alpha (TNFα) suppressor, and inﬂiximab, an anti-TNFα mouse/human chimeric
antibody, has been extensively studied in patients with alcoholic hepatitis. Liver transplantation remains the deﬁnitive therapy for
decompensated cirrhosis/alcoholic hepatitis despite the issues of recidivism, poor compliance with postoperative care, and being
a self-inﬂicted disease.
1.Introduction
Alcohol is a major risk factor for chronic disease burden all
over the world. Alcohol abusers and patients with alcoholic
liver disease (ALD) usually suﬀer negative consequences
from drinking such as signiﬁcant ﬁnancial burden, unem-
ployment, loss of family, accidental injury, or death [1].
Alcoholism is a physical dependence that includes impaired
control,craving,developmentoftolerance,anddevelopment
of withdrawal symptoms on abstinence.
ALD is a spectrum that ranges from fatty liver to alco-
holic steatohepatitis (ASH) and eventually cirrhosis. Simple
hepatic steatosis is the commonest histological ﬁnding and
occurs in 90% of heavy drinkers but is rapidly reversible with
abstinence. Alcoholic hepatitis or ASH occurs in up to 35%
of heavy drinkers and is usually a precursor of cirrhosis [2].
Epidemiological data suggest that a threshold of 80g
of daily alcohol in a male and 20–40g in a female for
an average of 10 to 12 years is necessary for causing
signiﬁcant alcohol-induced liver injury [3, 4]. However, only
a minority of individuals who consume alcohol in excess
develop signiﬁcant ALD. Synergistic factors such as chronic
hepatitis C, obesity, and genetic factors may accelerate
the development of ALD even at lower doses of alcohol
consumption.
ASH is a clinic-pathological syndrome that denotes hep-
atocellular necrosis and inﬂammation. The clinical spectrum
can range from being asymptomatic to developing overt liver
failure. There may be low-grade fever, jaundice, leukocytosis,
and mild elevation of transaminases. Histological features
of ASH include the presence of parenchymal necrosis,
Mallory bodies, and a perivenular neutrophilic inﬁltrate.
Other features that are commonly present include bridging
necrosis, fatty changes, bile duct proliferation, cholestasis,
and perivenular ﬁbrosis. Liver biopsy as a means of prognos-
tication in alcoholic hepatitis has mostly been replaced with
less invasive scoring systems. Patients with severe alcoholic
hepatitis can have clinical presentation almost similar to
those with decompensated cirrhosis, and it may become
diﬃcult to establish if such patients have associated cirrhosis
or not. But histologically, the majority of patients with severe
alcoholic hepatitis have either signiﬁcant ﬁbrosis or cirrhosis
liver. And alcoholic hepatitis with underlying cirrhosis is one
of the most important causes of acute on chronic liver failure
(ACLF) [5].2 International Journal of Hepatology
2.Prognostic Models in Patients with Alcoholic
LiverDisease
2.1. Discriminant Function. The Maddrey discriminant
function (DF) score remains the most commonly used pre-
dictive model and was developed to facilitate the assessment
of response in a clinical trial of corticosteroids in patients
with alcoholic hepatitis [6]. Modiﬁed DF is calculated as
= 4.6× (prolongation of prothrombin time in seconds) +
Serum bilirubin (mg/dL). A modiﬁed DF score >32 in the
presence of hepatic encephalopathy predicts >50% mortality
within 28 days in patients with alcoholic hepatitis [7, 8].
However, fatal outcomes have also been known to occur in
patients with modiﬁed DF score <32, and this low speciﬁcity
has suggested a need for alternative scoring systems.
2.2. Model for End-Stage Liver Disease (MELD). MELD
score was initially developed to predict survival in patients
with cirrhosis undergoing transjugular intrahepatic por-
tosystemic shunting (TIPSS). However, it has been found to
predict mortality in ASH, and a MELD score ≥21 (within
24 hours of presentation) is a good predictor of 90-day
mortality in these patients [9]. MELD and modiﬁed DF
scores (calculated within 24 hours of presentation) are
equivalent in predicting 30- and 90-day mortality in patients
with alcoholic hepatitis [10].
2.3. Glasgow Alcoholic Hepatitis Score (GAHS). GAHS was
d e v e l o p e di na ne ﬀort to overcome the low speciﬁcity of the
Maddrey DF and lack of an optimal predictive cutoﬀ point
for the MELD score. GAHS is a composite scoring system
based on age, serum bilirubin, blood urea nitrogen, PT, and
the peripheral leucocyte count. GAHS ≥9 is a predictor of
mortality and is more accurate than DF in predicting both
28- and 84-day mortality but is equivalent to MELD in
predicting 28-day mortality [11].
2.4. Lille Model. The Lille model incorporates age, renal
insuﬃciency, albumin, PT, bilirubin, and the evolution
of bilirubin on day 7 to predict 6-month mortality in
patients with severe alcoholic hepatitis who have received
corticosteroid therapy [12].
Arecentstudyshowedthatamongthevariousprognostic
scores for acute alcoholic hepatitis (Lille, Glasgow, and Mad-
drey scores) and cirrhosis (MELD, MELD-Na, and Child-
Turcotte-Pugh) in ALD patients treated with corticosteroids,
Lille score ≥0.45 and GAHS ≥9 were the most accurate
models for the prediction of mortality [13]. Although the
components may be diﬀerent in each of these scores, they
helpthephysicianstoidentifyasubsetofpatientswithhigher
mortality and requiring aggressive management.
3. Treatment of Alcoholic Liver Disease
3.1. General Management. One of the ﬁrst therapeutic
goals of patient management in patients with ALD is to
induce alcohol withdrawal. The administration of ﬂuid,
calories,vitamins,andmineralsisusuallyrequired.However,
overhydration should be avoided, as this can worsen ascites
and can precipitate variceal bleed. Vitamin K is usually
administered to patients who have a prolonged prothrombin
time, even though this regimen is typically ineﬀective
because coagulopathy reﬂects severity of underlying liver
disease. Correction of the coagulopathy with fresh frozen
plasma is not recommended in the absence of active
hemorrhage, because this treatment might increase the risk
ofvaricealhemorrhageinapatientwithportalhypertension.
Admission to a critical care unit should be considered for
unstable patients, and airway protection should be assured
in a patient with hepatic encephalopathy.
3.2. Abstinence. Abstinence is the cornerstone of therapy in
the management of ALD. Ideally, this includes rehabilitation
with a multidisciplinary approach. If abstinence is achieved,
clinical and histological improvement occurs, even if the
p a t i e n ti sa l r e a d yc i r r h o t i c[ 14–17]. Both psychological and
pharmacological approaches can be used to treat alcohol
dependence. Psychological interventions involve strategies
to educate and inform patients about the nature of their
problem and provide them with advice on how to change
their behavior. Psychosocial treatments such as cognitive
behavioral therapy and motivational enhancement therapy
have been shown to reduce alcohol intake in alcohol-
dependent patients [18].
As an addition to psychological therapies, many patients
might beneﬁt from pharmacological therapy. Both acam-
prosate and naltrexone have been demonstrated to reduce
the number of drinking days and increase abstinence rates
in randomized controlled trials [19]. Acamprosate, unlike
naltrexone, is well tolerated except in patients with Child
C cirrhosis and its beneﬁt seems to persist for at least 1
year after treatment withdrawal. Disulﬁram, an inhibitor of
acetaldehyde dehydrogenase, has been used for many years
in the management of alcohol-dependent patients, although
with conﬂicting results.
3.3. Nutrition. Patients with ALD are malnourished for a
number of reasons, including malabsorption, the induction
of a catabolic state, and the replacement of calories with
alcohol. Protein-caloric malnutrition has also been demon-
strated to correlate with short-term and long-term mortality
in alcoholics. Hence, malnutrition should be actively sought
in such patients, and replacement should be commenced
accordingly. The eﬃcacy of nutritional therapy in ASH has
been evaluated in numerous clinical trials. Although various
results have been reported, most studies have shown that
nutritional therapy improves liver function and histology.
Enteral feeding is preferredto parenteral nutrition. Although
protein ingestion is a theoretical risk factor for the devel-
opment of hepatic encephalopathy, protein feeding is well
tolerated, and protein should not be routinely restricted in
patients with ASH.
Two randomized controlled trials have looked at the
eﬀects of nutritional therapy. The ﬁrst study compared
enteral tube feeding of an energy-dense formula (>2,000kcal
daily) with an isocaloric standard oral diet in 35 randomlyInternational Journal of Hepatology 3
allocated, severely malnourished, cirrhotic patients. In-
hospitalmortalitywassigniﬁcantlylowerintheenteralgroup
(12% versus 47%) [20]. The second study which compared
enteral feeding with steroids in 71 patients with acute, severe
ASH found that there was no diﬀerence in mortality between
the groups during the 28-day treatment period. However,
the mortality rate was lower in the enterally fed group in
the year following treatment [21]. In summary, nutritional
supplementation could have a role in the improvement of
medium-term to long-term survival in patients with severe
ASH. The American College of Gastroenterology guidelines
recommend 1.2 to 1.5g/kg of protein and 35 to 40kcal/kg of
body weight for patients with ALD [22].
3.4. Glucocorticoids. Glucocorticoids are the most intensely
studied and yet most hotly debated treatment for acute
alcoholic hepatitis. The rationale for glucocorticoid use is
to block cytotoxic and inﬂammatory pathways in alcoholic
hepatitis. Glucocorticoids have been shown to decrease
proinﬂammatory cytokines and intercellular cell adhesion
molecule 1 expression and inhibit neutrophil activation and
have demonstrated short-term histological improvement in
patients with alcoholic hepatitis.
ResultsfromtrialsofglucocorticoidsforALDarevariable
and depend on the nature of the trial and the group of
patients recruited as the study population. Even among
glucocorticoidstrialswithbeneﬁcialresults,enrolledsubjects
were heterogeneous with variable deﬁnitions of randomiza-
tion and blinding and without homogeneous inclusion or
exclusion criteria. Diﬀerent types of steroids for diﬀerent
durations and diﬀerent criteria were used for treatment.
Steroid use in alcoholic hepatitis raises the risk of infection
in an already immunocompromised host. Some trials have
demonstrated higher mortality in the glucocorticoid group
compared to the placebo group [23–26]. Associated with
this higher mortality, a greater incidence of fungal infections
among patients receiving glucocorticoids has been reported
by some authors [25]. A meta-analysis on this subject,
published in 1990, demonstrated a protective eﬀect of
glucocorticoidsinhighqualitytrials.Thiswasespeciallysoin
studies that excluded patients with gastrointestinal bleeding
but included those with hepatic encephalopathy [27]. But
another meta-analysis by Christensen and Gluud found no
beneﬁt once they attempted to control for confounders
[28]. A subsequent reanalysis of the same 3 randomized,
controlled trials in Christiansen and Gluud’s meta-analysis,
which pooled raw data from more than 200 patients with
modiﬁed DF ≥32, found a 28-day survival beneﬁt of
glucocorticoids(85%)versusplacebo(65%).Inpatientswith
modiﬁed DF ≥32, treatment with glucocorticoids improved
short-term(28-day)survival,withmortalitydecreasingfrom
35% in controls to 15% with steroids. Conversely, patients
with modiﬁed DF <32 had a >90% survival rate without
steroids. The number of patients who needed to be treated to
save 1 patient was 5 [29]. Another meta-analysis of 15 trials
with 721 randomized patients reported that the evidence in
favor of glucocorticoids was based on heterogeneous trials
of low quality [30]. Recently using individual patient data
from more than 400 patients, Mathurin et al. demonstrated
improved survival with corticosteroid treatment. Patients
were classiﬁed as complete responders (Lille score ≤0.16;
≤35th percentile), partial responders (Lille score 0.16–0.56;
35th–70th percentile), and null responders (Lille ≥0.56;
≥70th percentile). 28-day survival was strongly associated
with these groupings (91% versus 79% versus 53%, P<
0.0001). Corticosteroids had a signiﬁcant eﬀect on 28-day
survivalincompleterespondersandinpartialrespondersbut
notinnullresponders[31].Thelong-termbeneﬁtofsteroids
is diﬃcult to assess as the various trials had diﬀering follow-
up periods, and unless the patient abstains from alcohol
completely, alcoholic hepatitis is likely to recur. The survival
beneﬁt of corticosteroid therapy has not been found to
persist beyond 1 year.
Despite having 13 randomized controlled trials and 6
meta-analyses of steroids as a treatment for ASH, concerns
over their use continue. Although corticosteroids are prob-
ably beneﬁcial in patients with severe disease, mortality on
treatment remains high, particularly when renal impairment
is present, and treatment is contraindicated in a relatively
large number of patients with concomitant infection and
gastrointestinal bleeding.
3.5. Antitumor Necrosis Factor Alpha Treatment
3.5.1. Pentoxifylline. Elevated tumor necrosis factor alpha
(TNFα) levels have been found to be predictive of poor
survival in patients with alcoholic hepatitis. Pentoxifylline
is a nonselective phosphor-di-esterase inhibitor and a
TNFα suppressor. In 1991, a study of pentoxifylline for
severe alcoholic hepatitis (DF ≥ 32) reported a reduction in
the development of hepatorenal syndrome and mortality in
comparison with placebo [32]. A subsequent study of 101
patients from the same center supported the earlier ﬁndings,
demonstrating a 40% reduction in mortality in comparison
with placebo. The number needed to treat to prevent 1 death
was 4.7. However, in this study, there was no demonstrable
improvement in routine liver function tests or liver histology
and the better survival was predominantly due to decreased
incidence of hepatorenal syndrome [33].
In another study, 29 patients who did not respond to
corticosteroids (identiﬁed by an absence of an early decline
in bilirubin) were switched to pentoxifylline for 28 days and
compared to 58 other matched patients who persisted with
corticosteroidtherapy.Nosurvivalbeneﬁtwasobservedwith
pentoxifylline at 2 months [34]. Thus, although some data
suggest a beneﬁt with pentoxifylline in alcoholic hepatitis,
it is unclear whether its beneﬁt extends beyond possibly
preventing hepatorenal syndrome.
3.5.2. Inﬂximab. Inﬂiximab is an anti-TNFα mouse/human
chimeric antibody and has been extensively studied in
alcoholic hepatitis. Early reports were encouraging, demon-
strating improved survival rates, improved Maddrey scores,
or improved laboratory parameters. However, the largest
randomized, controlled trial to date, which enrolled 36
patients and compared a combination of prednisolone4 International Journal of Hepatology
(40mg/day) and inﬂiximab (10mg/kg 3 times per week in
weeks 0, 2, and 4) to prednisolone and placebo in alcoholic
hepatitis was terminated prematurely [35]. More deaths
had occurred in the group treated with prednisolone and
inﬂiximab. Whether this risk was related to the higher doses
of inﬂiximab used, more ill patients being recruited in this
trial in comparison with earlier studies, the combined use
of prednisolone and inﬂiximab, or the possible unsuitability
of inﬂiximab for the treatment of alcoholic hepatitis is still
debatable.
3.5.3. Etanercept. A small, uncontrolled study evaluated the
use of etanercept in 13 patients with moderate to severe
alcoholic hepatitis. Two patients died within 32 days, and 3
developed serious adverse events (infection, gastrointestinal
bleeding, and hepatorenal syndrome) mandating withdrawal
of the drug [36]. A more recent multicenter, randomized,
double-blind, placebo-controlled study of etanercept in 48
patients with severe alcoholic hepatitis (deﬁned as MELD
≥15) found no diﬀerence in the 1-month mortality rates
in the 2 groups on an intention-to-treat analysis [37].
Alarmingly, the 6-month mortality in the etanercept group
was signiﬁcantly higher in comparison with the controls.
Rates of serious adverse infectious events were also sig-
niﬁcantly higher in the etanercept group. These results
have considerably dampened the enthusiasm for using anti-
TNFα agents in patients with severe ASH.
3.6. Antioxidant Cocktails. Antioxidants have been tried
in alcoholic hepatitis as oxidative stress is a key factor
in its pathogenesis. However, results have failed to show
any convincing beneﬁt from their use. Phillips et al., who
compared corticosteroids to an antioxidant cocktail (β-
carotene, vitamins C and E, selenium, methionine, allop-
urinol, desferrioxamine, and N-acetylcysteine), reported
inferior survival rates in comparison with corticosteroids at
30 days [38]. Another study stratiﬁed patients with severe
alcoholic hepatitis by gender and corticosteroid treatment.
The active group received a loading dose of N-acetylcysteine
(150mg/kg followed by 100mg/kg/day for 1 week) and daily
dosesofvitaminsAandE,biotin,selenium,zinc,manganese,
copper, magnesium, folic acid, and coenzyme Q for 6
months. Antioxidant therapy showed nobeneﬁt,either alone
or in combination with corticosteroids [39]. A more recent
studyof87patientswithseverealcoholichepatitis(deﬁnedas
modiﬁed Maddrey DF ≥32) randomized patients to receive
either corticosteroids with N-acetylcysteine infusion for 5
days or corticosteroids alone [40]. Although patients in the
N-acetylcysteine group had better 1-month survivals, this
eﬀect did not persist at 3 and 6 months.
3.7. S-Adenosyl Methionine. S-Adenosyl methionine (SAMe)
is a precursor of glutathione that theoretically might be
protective in alcohol-induced liver injury. In a Cochrane
database review of 9 randomized trials that combined a
heterogeneoussampleof434patientswithALD,SAMefailed
to show a survival beneﬁt [41]. Only 1 trial of 62 patients
deemed to have adequate methodology and outcome report-
ing and good quality suggested beneﬁt (improved survival
and delay to liver transplantation) with 2 years of SAMe
treatment for Child’s class A and B alcoholic cirrhosis [42].
3.8. Treatment of Hepatorenal Syndrome Associated with Alco-
holic Hepatitis. In patients with severe ASH, the develop-
ment of renal failure is associated with a survival of less than
10% even with intensive management. The most signiﬁcant
advance in the management of patients with advanced liver
disease over the past decade has been the introduction
of albumin infusions combined with splanchnic vasocon-
strictor agents for patients with hepatorenal syndrome.
Although no randomized trials have speciﬁcally examined
this form of therapy in patients with ASH, the previously
reported high mortality in ASH patients with hepatorenal
syndrome suggests that albumin infusions combined with
splanchnic vasoconstrictor agents would have a signiﬁcant
and beneﬁcial eﬀect on patient survival. The usefulness of
pentoxyfylline in this clinical setting has been mentioned
earlier.
3.9. Liver Transplantation in ALD. Orthotopic liver trans-
plantation (OLT) remains the deﬁnitive therapy for decom-
pensated cirrhosis due to ALD despite continued alcohol
abstinence. Short-term (1- to 7-year) graft survival and
patient survival remain at par with, if not superior to,
survival with non-ALD if the patient remains abstinent.
Bellamy et al. reported that in 123 patients who were
transplanted, patient survival at 1, 5, and 7 years was 84%,
72%, and 64%, respectively. Graft survival was 81%, 66%,
and 50%, respectively, over the same period [43]. The 1- and
5-year patient and graft survival rates for all patients with
cirrhosis were 86.9%/73.4% and 82.4%/67.4%, respectively
[44].
However, OLT for ALD patients continues to fuel
controversy, including issues of recidivism, potentially poor
compliance with postoperative care, and inherent biases
against alcoholics, such as concern about using scarce organs
for what is often perceived to be a self-inﬂicted disease.
DiMartini et al.’s prospective study of alcoholic recipients
found that 22% had used some alcohol by the end of the
ﬁrst year post-OLT and 42% had by 5 years, of whom 26%
had a binge drinking pattern [45]. Such a wide range of
relapse rates may stem fromvarying deﬁnitions of recidivism
and methods of eliciting alcohol consumption data. Most
studies addressing recidivism in the past 20 years have used
the “any use” deﬁnition of alcohol relapse. However, a return
to drinking does not necessarily mean excessive drinking.
Furthermore, Fabrega et al.’s report of patients who had
returned to drinking revealed no decreased compliance with
other medical care, including immunosuppressant therapy
[46]. Pﬁtzmann et al. stratiﬁed relapsers into slips and
harmful drinking, revealing signiﬁcantly worse 5- and 10-
year survival rates (69.5% and 20%) among “harmful”
drinkers versus abstainers (90.3% and 81.5%) [47].
A major focus in determining candidacy for liver
transplantation in ALD has been identifying factors toInternational Journal of Hepatology 5
predict posttransplant recidivism. Pretransplant duration of
abstinence from alcohol was the ﬁrst predictive factor ana-
lyzed. Other medical and social variables can be associated
with high relapse rates, including tobacco consumption,
noncompliance to follow-up clinic visits, and mental illness.
A 2008 meta-analysis of 50 studies looking at predictors
of recidivism found 3 signiﬁcant, albeit modest, variables:
a poor social support system, a family history of alco-
hol abuse/dependence, and pretransplant abstinence of 6
months or less [48].
Pre-OLT abstinence, especially the 6-month rule,
remains contentious. Studies over the years have provided
convincing data for and against the 6-month abstinence
requirement. Lucey et al. suggested that this 6-month
period of abstinence would allow the native liver to
recover with medical management and possibly obviate
transplantation [49]. However, this minimal period of
abstinence is sometimes waived if the patient is deemed too
ill to survive beyond 6 months without a liver transplant.
One study showed that recovery in decompensated alcoholic
cirrhosis by alcohol abstinence can be predicted within
3 months of abstinence by the monitoring of clinical
signs via the Child-Pugh scoring system (serum bilirubin,
albumin, international normalized ratio, ascites, and hepatic
encephalopathy) [50]. This study by Veldt et al. found that
although such improvement in liver function can take place
within 3 months of abstinence, some abstinent patients
die within 6 months; this has led some authors to suggest
reducing the period of abstinence from 6 to 3 months. Yet,
abstinence less than 12 months was recently identiﬁed as
a signiﬁcant risk factor for relapse in a large retrospective
study of OLT recipients [50].
Finally, an increasing concern of late is the high risk for
de novo malignancies in long-term survivors transplanted
for ALD. Although posttransplantation lymphoprolifera-
tive disorder and nonmelanoma skin cancer remain the
most common malignancies after liver transplantation, the
incidence of esophageal cancer is signiﬁcantly increased
in patients with alcohol as the etiology of end-stage liver
disease. Duvoux et al.’s prospective study showed a signif-
icantly higher incidence of malignancies in patients with
ALD compared to those with non-ALD etiologies [51]. They
also detected squamous cell carcinoma of the oropharynx
or esophagus only in recipients transplanted for ALD.
Risk factors undoubtedly include the cumulative eﬀects of
alcohol and, in most cases, smoking with posttransplant
immunosuppression. Thus, regular ear, nose, and throat
examinations appear justiﬁed in patients transplanted for
ALD.
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